PE 22-28 vs Vasopressin
Updated August 24, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of PE 22-28 and Vasopressin (also searched as Vasopressin vs PE 22-28) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
PE 22-28 centers on metabolic, while Vasopressin leans toward neuro. On indexed research, PE 22-28 is ahead (PE 22-28: 29 studies, Human evidence; Vasopressin: 24, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •PE 22-28 is strongest for metabolic; Vasopressin for neuro.
- •Evidence: PE 22-28 Human evidence (29 studies) vs Vasopressin Human clinical (24).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
Metabolic regulation | Gestational diabetes
Vasopressor | Blood pressure management
PE 22-28 vs Vasopressin: side-by-side
| Metric | PE 22-28 | Vasopressin |
|---|---|---|
| Class | Metabolic | Metabolic |
| Regulatory status | Research use only | FDA-approved |
| Evidence grade | Human evidence | Human clinical |
| Studies indexed | 29 | 24 |
| Research level | Limited Research | FDA Approved |
| Strongest effect | Metabolic & appetite | Neuro & mood |
| Healing & recovery | 2.0▲ | 2.0▲ |
| Muscle & body comp | 0.0 | 1.0▲ |
| Metabolic & appetite | 3.0▲ | 3.0▲ |
| Neuro & mood | 0.0 | 4.0▲ |
| Sleep & circadian | 0.0 | 2.0▲ |
| Inflammation & immune | 1.0 | 3.0▲ |
| Skin & aesthetics | 0.0 | 1.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | PE 22-28 | Vasopressin |
|---|---|---|
| Mechanism | — | Vasopressin receptor agonist (V1A and V2 receptors) |
| Route | — | Subcutaneous injection |
| Half-life | — | ~10–20 min |
| Time to peak | — | 30–60 min |
| Duration of action | — | 2–8 hours |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is PE 22-28?
PE 22-28 is a peptide that has garnered attention in various research contexts, particularly in relation to vascular health and metabolic conditions. Its potential implications in gestational diabetes and placental function are areas of ongoing investigation.
Full PE 22-28 profile, mechanism & studies →What is Vasopressin?
Research peptide discovered via AI researcher. peptide-based therapeutic
Full Vasopressin profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Even | Both ~2.0/5 |
| Muscle | Vasopressin | 1.0/5 effect signal |
| Metabolic | Even | Both ~3.0/5 |
| Neuro | Vasopressin | 4.0/5 effect signal |
| Sleep | Vasopressin | 2.0/5 effect signal |
| Inflammation | Vasopressin | 3.0/5 effect signal |
| Skin | Vasopressin | 1.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack PE 22-28 and Vasopressin?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
PE 22-28 vs Vasopressin: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
PE 22-28 has 29 approved studies indexed (Human evidence), and Vasopressin has 24 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is PE 22-28 or Vasopressin better?
It depends on your goal. PE 22-28 is strongest for metabolic; Vasopressin for neuro. PE 22-28 has more indexed studies (29). See the goal-by-goal breakdown above.
Is PE 22-28 or Vasopressin better for weight loss?
They score similarly on the metabolic/appetite axis in the community data.
Is PE 22-28 or Vasopressin better for muscle?
Vasopressin leads on the muscle & body-composition axis (1.0/5).
Which has more research, PE 22-28 or Vasopressin?
PE 22-28 has 29 approved studies indexed (Human evidence); Vasopressin has 24 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack PE 22-28 and Vasopressin?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of PE 22-28 vs Vasopressin?
PE 22-28: no community-reported effects logged yet. Vasopressin: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is PE 22-28 or Vasopressin FDA-approved?
PE 22-28 is a research-use compound and is not FDA-approved. Vasopressin is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Vasopressin better than PE 22-28?
For neuro, Vasopressin has the edge; for metabolic, PE 22-28 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed August 24, 2026.